Company intelligence / Profile preview

Novomedison

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Novomedison is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of innovative immune cell therapies for oncology. The company utilizes its proprietary i-CRT (Immune-Cell Reprogramming Technology) platform to engineer CAR-T and TCR-T products designed to overcome the immunosuppressive microenvironment of solid tumors. Its lead candidate, NM-002, is a GPC3-targeted CAR-T therapy currently undergoing clinical evaluation for patients with advanced hepatocellular carcinoma. Novomedison aims to improve the efficacy and persistence of cell therapies through advanced genetic engineering and immune cell modulation.

Therapeutic areas: Oncology
Modalities: Cell therapyCAR-T cell therapyT cell therapy
Industry: Biotech

Drug pipeline

1 asset

poseltinib

Beyond the preview

Go deeper on Novomedison.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novomedison.

Explore the full profile